Skip to main content
. 2020 Jan 28;4(2):408–419. doi: 10.1182/bloodadvances.2019001021

Figure 3.

Figure 3.

Expansion of key cell subsets; namely, CD20+B cells, CD8+CD11bT cells, and CD16+CD57NK cells, significantly positively affected 2-year OS. There were no significant differences in CIR or proportions of high vs low cell counts for CD20+ B cell and CD8+CD11b- T cell subsets. NRM benefits were found to be lower (range, 17%-21%) in patients with early IR of these cells. CIR was confirmed to be approximately 26% lower in patients with early IR of CD16+CD57 NK cells.